Drugs of Abuse (DOA) Testing Market Report 2026

Drugs of Abuse (DOA) Testing Market Overview

• Drugs of Abuse (DOA) Testing market size has reached to $7.97 billion in 2025 • Expected to grow to $12.17 billion in 2030 at a compound annual growth rate (CAGR) of 8.8% • Growth Driver: Rising Demand For Drug Abuse Treatment Drives Growth In The DOA Testing Market • Market Trend: Innovative Solutions In The Drugs Of Abuse Testing Market Are Software-As-A-Service (SAAS) Platforms For Enhanced Drug Discovery And Development • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

The key promising market opportunities in the drugs of abuse (doa) testing market include: • Criminal Justice (Segmentation By Application) → Expected gain of $1778.31 Million • Pain Management (Segmentation By Application) → Expected gain of $1762.05 Million • Consumables (Segmentation By Product And Service) → Expected gain of $1747.08 Million

What Is Covered Under Drugs of Abuse (DOA) Testing Market?

Drug of abuse (DOA) testing refers to the examination of a substance, such as a drug, chemical, or plant product, that is usually treated recreationally. It includes marijuana, cocaine, opioids, amphetamines, alcohol, and PCP, which are tested for on a drug panel. The patient's urine, saliva, blood, hair, or sweat are used in this clinical screening procedure. The main products and services for drug of abuse (DOA) testing are analyzers, rapid testing devices, consumables, and laboratory services. An analyzer is a device that automatically measures the chemical concentration of one or more components or another associated physical quantity, continuously or intermittently. There are sample types included such as urine, hair, oral fluid, and breath, and are available in various applications such as pain management, criminal justice, and workplace screening. The end users involve hospitals, diagnostic laboratories, forensic laboratories, and others.

What Is The Drugs of Abuse (DOA) Testing Market Growth Forecast?

The drugs of abuse (doa) testing market size is expected to see strong growth in the next few years. It will grow to $12.17 billion in 2030 at a compound annual growth rate (CAGR) of 8.8%. The growth in the forecast period can be attributed to remote workplace testing demand, oral fluid testing growth, real-time data integration, regulatory enforcement expansion, public health monitoring programs. Major trends in the forecast period include rising adoption of workplace drug screening programs, growing demand for rapid point-of-care testing, expansion of multi-panel drug testing kits, increased use of laboratory confirmation testing, integration of digital reporting and data management.

What Is The Driver Of The Drugs of Abuse (DOA) Testing Market?

Increasing demand for drug abuse treatment is expected to propel the growth of the drugs of abuse (DOA) testing market going forward. Drug abuse or substance abuse refers to the use of a substance in quantities that are harmful to the user or others. Drug testing aids in the identification of compounds that are not normally found in the body. The process starts with a screening test, which is followed by a second test to find and/or confirm the presence of a substance or substances, so increasing demand for drug abuse treatment will propel the market's growth. For instance, in December 2023, the Government of the United Kingdom (GOV. UK), a UK-based government platform, reported that between April 2022 and March 2023, 290,635 adults accessed drug and alcohol services, a slight increase from 289,215 in the previous year. Treatment admissions also rose to 137,749, compared to 130,490 and 133,704 in the prior two years. Therefore, increasing demand for drug abuse treatment is driving the drug of abuse (DOA) testing market.

How Will The Drivers Impact Growth In The Global Drugs Of Abuse (DOA) Testing Market?

• Growing Healthcare Awareness (High) – The growing healthcare awareness will become a key driver of growth in the drugs of abuse (DOA) testing market by 2030. Early detection and prevention of substance abuse are increasing the demand for drugs of abuse (DOA) testing. Governments and healthcare providers are implementing drug screening programs in workplaces, hospitals, and rehabilitation centers. Increased public knowledge about addiction risks is also encouraging more people to undergo drug testing. As a result, the growing healthcare awareness is anticipated to contributing to a 2.0% annual growth in the market. • Rise In Road Safety Concerns (Medium) – The rise in road safety concerns will emerge as a major factor driving the expansion of the drugs of abuse (DOA) testing market by 2030. Impaired driving due to substance abuse poses significant risks, leading to increased demand for drugs of abuse (DOA) testing. Governments and law enforcement agencies are implementing testing protocols to ensure safer roads. The demand is also fueled by heightened awareness of the dangers of driving under the influence of drugs. Consequently, the rise in road safety concerns capabilities is projected to contributing to a 1.5% annual growth in the market. • Rise In Drug Smuggling And Trafficking (Medium) – The rise in drug smuggling and trafficking within digital manufacturing processes will serve as a key growth catalyst for the drugs of abuse (DOA) testing market by 2030. Authorities are increasingly focused on combating illegal drug use and distribution, driving the demand for Drugs of Abuse (DOA) testing. Enhanced border security and detection measures require more accurate and efficient testing solutions. This trend is further fueled by the growing sophistication of drug trafficking networks. Therefore, this rise in drug smuggling and trafficking operations is projected to supporting to a 1.3% annual growth in the market. • Expansion Of Rehabilitation And Treatment Centers (Medium) – The expansion of rehabilitation and treatment centers will become a significant driver contributing to the growth of the drugs of abuse (DOA) testing market by 2030. Rehabilitation and treatment centers require accurate Drugs of Abuse (DOA) testing to monitor recovery and prevent relapse. With the increasing number of facilities, the need for reliable testing solutions is growing. Effective testing is essential for supporting patient care and treatment outcomes. Consequently, the expansion of rehabilitation and treatment centers strategies is projected to contributing to a 1.0% annual growth in the market.

How Will The Restraints Impact Growth In The Global Drugs Of Abuse (DOA) Testing Market?

• High Costs Of Advanced Testing Equipment (High) – High Costs Of Advanced Testing Equipment will restrict the growth of the Drugs Of Abuse (DOA) Testing market during the forecast period. Advanced drug testing equipment, including mass spectrometers and immunoassay analyzers, requires significant capital investment. The high costs of equipment, consumables, and maintenance create financial barriers for smaller laboratories and healthcare facilities. Cost constraints may limit the availability of advanced testing services, particularly in developing regions, affecting market growth and testing accessibility. • Risk Of False Positives And Negatives (Medium) – Risk Of False Positives And Negatives will restrict the growth of the Drugs Of Abuse (DOA) Testing market during the forecast period. Drug testing methods can produce false positive or false negative results due to cross-reactivity, specimen adulteration, or testing limitations. The risk of inaccurate results creates legal and ethical concerns for employers, law enforcement, and healthcare providers. False results can lead to wrongful accusations, missed diagnoses, and legal challenges, affecting confidence in drug testing and potentially limiting market growth.

Key Players In The Global Drugs of Abuse (DOA) Testing Market

Major companies operating in the drugs of abuse (doa) testing market are Siemens AG, F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Laboratory Corporation of America Holdings, Quest Diagnostics Inc., bioMérieux Inc., Dragerwerk AG & Co. KGaA, Aegis Sciences Corporation, NMS Labs, Clinical Reference Laboratory Inc., Cordant Health Solutions, Millennium Health, ACM Global Laboratories, Psychemedics Corporation, Alfa Scientific Designs Inc., Alere Toxicology Services, Omega Laboratories Inc., BioTek Laboratories, Premier Biotech Inc., Dominion Diagnostics LLC, Randox Toxicology Ltd., Cansford Laboratories Ltd., United States Drug Testing Laboratories Inc., American Bio Medica Corporation, Confirm BioSciences, Immunalysis Corporation, Medtox Diagnostics Inc., Forensic Fluids Laboratories

Global Drugs of Abuse (DOA) Testing Market Trends and Insights

Major companies operating in the drugs of abuse (DOA) testing market are focusing on developing innovative products such as software-as-a-service (SaaS) platforms to enhance testing efficiency, improve data management, and strengthen their competitive position. A software-as-a-service (SaaS) platform refers to a cloud-based application hosted by a third-party provider and accessed via the internet, enabling users to streamline workflows, analyze complex datasets, and gain actionable insights without the need for local software installation. For instance, in December 2023, Merck KGaA, a US-based science and technology company, launched Addison, an advanced drug discovery software platform that integrates computer-aided drug design, machine learning, and generative AI to accelerate drug development. The platform provides synthesis recommendations for virtual molecules, connects digital drug design with practical manufacturability, and uncovers hidden insights from large datasets, ultimately increasing the likelihood of delivering effective new therapies to patients.

What Are Latest Mergers And Acquisitions In The Drugs of Abuse (DOA) Testing Market?

In June 2024, Premier Biotech Inc., a US-based biotechnology company, acquired Desert Tox LLC for an undisclosed amount. Through this acquisition, Premier Biotech aims to broaden its portfolio of affordable drug misuse screening solutions and improve the accessibility and effectiveness of drug testing services. Desert Tox LLC is a US-based company specializing in toxicology and drug testing solutions.

What Defines the Drugs of Abuse (DOA) Testing Market?

The drugs of abuse (DOA) testing market includes revenues earned by entities by providing services such as analyzers, rapid testing devices, consumables, and laboratory services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Drugs of Abuse (DOA) Testing Market Report 2026?

The drugs of abuse (doa) testing market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the drugs of abuse (doa) testing industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.